Bank of New York Mellon Corp Has $3.70 Million Stock Holdings in Certara, Inc. $CERT

Key Points

• Bank of New York Mellon cut its Certara stake by 40% in the first quarter, selling 432,312 shares and retaining 648,530 shares worth approximately $3.70 million. Institutional investors collectively own 73.96% of Certara.
• Analysts maintain a consensus “Hold” rating with an average price target of $8.28, despite several firms lowering their targets and Barclays raising its target to $7.50.
• Certara’s latest results fell short of expectations: quarterly revenue declined 10.8% year over year to $93.27 million, while EPS came in at $0.08 versus the $0.09 consensus estimate.

Bank of New York Mellon Corp decreased its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 40.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 648,530 shares of the company's stock after selling 432,312 shares during the period. Bank of New York Mellon Corp owned 0.42% of Certara worth $3,697,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in CERT. Northwestern Mutual Wealth Management Co. increased its stake in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company's stock valued at $26,000 after acquiring an additional 2,870 shares in the last quarter. Osaic Holdings Inc. boosted its stake in Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock worth $41,000 after acquiring an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company's stock worth $69,000 after acquiring an additional 4,930 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new stake in Certara in the first quarter worth $78,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Certara in the second quarter worth $83,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Stephens reduced their target price on Certara from $10.00 to $9.00 and set an "overweight" rating for the company in a research note on Tuesday, May 12th. Morgan Stanley dropped their price target on Certara from $11.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 12th. BMO Capital Markets cut their price target on Certara from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Tuesday, May 12th. KeyCorp reduced their price objective on Certara from $10.00 to $8.00 and set an "overweight" rating for the company in a research note on Monday, April 13th. Finally, Barclays boosted their price objective on Certara from $6.50 to $7.50 and gave the company an "equal weight" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $8.28.

Certara Stock Performance

Shares of Certara stock opened at $8.13 on Friday. Certara, Inc. has a 52 week low of $4.45 and a 52 week high of $13.88. The company has a quick ratio of 1.88, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The business has a 50 day moving average price of $6.52 and a 200-day moving average price of $6.54. The company has a market cap of $1.24 billion, a PE ratio of -18.07 and a beta of 1.44.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The company had revenue of $93.27 million for the quarter, compared to analysts' expectations of $98.09 million. During the same period in the previous year, the firm earned $0.07 EPS. The firm's quarterly revenue was down 10.8% on a year-over-year basis. Equities analysts anticipate that Certara, Inc. will post 0.24 earnings per share for the current fiscal year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company's offerings are divided into software tools and consulting services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source